All Stories

  1. Chronic spontaneous urticaria remission definition and therapy stepping down: World Allergy Organization position paper
  2. An algorithm for the diagnosis of beta‐lactam allergy, 2024 update
  3. Predictors of biological therapy in severe asthma patients. An ambispective study from the BIOBADALER consortium.
  4. Diagnosis, Pathogenesis and Treatment of Chronic Spontaneous Urticaria
  5. An algorithm for the diagnosis, pathogenesis and treatment of chronic spontaneous urticaria, 2024 update
  6. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria
  7. Serum Amyloid A as a Potential Biomarker for Disease Activity in Chronic Spontaneous Urticaria
  8. Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial
  9. Chronic Spontaneous Urticaria: The Role and Relevance of Autoreactivity, Autoimmunity, and Autoallergy
  10. In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria
  11. Determinants of effective treatment coverage for posttraumatic stress disorder: findings from the World Mental Health Surveys
  12. Unveiling chronic spontaneous urticaria pathophysiology through systems biology
  13. Cost-utility analysis of the UPRIGHT intervention promoting resilience in adolescents
  14. Incidence of mental disorders in the general population aged 1–30 years disaggregated by gender and socioeconomic status
  15. The relationship between air pollution and multimorbidity: Can two birds be killed with the same stone?
  16. Corrigendum to ‘Suicide-related thoughts and behavior and suicide death trends during the COVID-19 in the general population of Catalonia, Spain’ [European Neuropsychopharmacology 56 (2021) 4–12]
  17. The effectiveness of a “EspaiJove.net”- a school-based intervention programme in increasing mental health knowledge, help seeking and reducing stigma attitudes in the adolescent population: a cluster randomised controlled trial
  18. Medical algorithm: Diagnosis and management of histaminergic angioedema
  19. Mental health symptoms 1 year after the COVID-19 outbreak in Spain: The role of pre-existing mental disorders and their type
  20. Angioedema severity and impact on quality of life: Chronic histaminergic angioedema versus chronic spontaneous urticaria
  21. The associations between traumatic experiences and subsequent onset of a substance use disorder: Findings from the World Health Organization World Mental Health surveys
  22. Classification and Treatment of Angioedema without Wheals: A Spanish Delphi Consensus
  23. Health Inequalities by Sexual Orientation: Results from the 2016–2017 Barcelona Health Survey
  24. The Association of Age With Depression, Anxiety, and Posttraumatic Stress Symptoms During the COVID-19 Pandemic in Spain: The Role of Loneliness and Prepandemic Mental Disorder
  25. Clinical and immunological data from chronic urticaria onset after mRNA SARS‐CoV‐2 vaccines
  26. Reliability of a novel electro‐medical device for wheal size measurement in allergy skin testing: An exploratory clinical trial
  27. Consensus on the Definition of Control and Remission in Chronic Urticaria
  28. Increased risks for mental disorders among LGB individuals: cross-national evidence from the World Mental Health Surveys
  29. Determinants of effective treatment coverage for major depressive disorder in the WHO World Mental Health Surveys
  30. Unraveling the Diagnosis of Kiwifruit Allergy: Usefulness of Current Diagnostic Tests
  31. Autoimmune chronic spontaneous urticaria
  32. Urticaria crónica espontánea : abordaje diagnóstico y terapéutico
  33. Validation of a commercial allergen microarray platform for specific immunoglobulin E detection of respiratory and plant food allergens
  34. Biomarkers Commonly Associated with Urticaria Severity Do Not Correlate With Angioedema Activity Scores
  35. [Artículo traducido] Práctica clínica diaria en el manejo de la urticaria crónica en España: resultados del estudio UCREX
  36. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper
  37. Validation of novel recipes for masking peanuts in double-blind, placebo-controlled food challenges
  38. High prevalence of obstructive sleep apnea syndrome in Spain’s Stroke Belt
  39. Erratum to "IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper" [World Allergy Organ J 13/2 (2020) 100080]
  40. A Comparative Study of Sex Distribution, Autoimmunity, Blood, and Inflammatory Parameters in Chronic Spontaneous Urticaria with Angioedema and Chronic Histaminergic Angioedema
  41. ARADyAL: The Spanish Multidisciplinary Research Network for Allergic Diseases
  42. Role of nanostructures in allergy: Diagnostics, treatments and safety
  43. Approach to Occupational Contact Dermatitis in an Industrialized Region of Spain
  44. Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria
  45. A Specialized Therapeutic Approach to Chronic Urticaria Patient’s Refractory to H1-Antihistamines Improves the Burden of the Disease. The Spanish AWARE Experience
  46. Identification and Characterization of IgE‐Reactive Proteins and a New Allergen (Cic a 1.01) from Chickpea (Cicer arietinum)
  47. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper
  48. Histaminergic angioedema: similarities and differences between isolated angioedema and chronic urticaria with angioedema
  49. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020
  50. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria
  51. Negative autoimmunity in a Spanish pediatric cohort suspected of type 1 diabetes, could it be monogenic diabetes?
  52. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study
  53. Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial
  54. Adjuvants in Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune Response
  55. Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study)
  56. Lifetime and 12‐month treatment for mental disorders and suicidal thoughts and behaviors among first year college students
  57. Mental disorder comorbidity and suicidal thoughts and behaviors in the World Health Organization World Mental Health Surveys International College Student initiative
  58. The role impairment associated with mental disorder risk profiles in the WHO World Mental Health International College Student Initiative
  59. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis
  60. DIAGNOSTIC PERFORMANCE OF DIFFERENT METHODS FOR DETECTION OF SENSITIZATION TO PRU P 3 IN SPAIN
  61. Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe
  62. Biologics in chronic urticaria
  63. Allergy rhinitis: similarities and differences between children and adults
  64. Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis
  65. Improvement of the Elevated Tryptase Criterion to Discriminate IgE- From Non–IgE-Mediated Allergic Reactions
  66. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria
  67. Adjuvants for allergy immunotherapeutics
  68. Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
  69. Predicting return of chronic idiopathic urticaria symptoms following omalizumab treatment discontinuation: Exploratory analysis of phase III data
  70. Angio-oedema without hives, IgE and omalizumab
  71. Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe
  72. Sustained Effect and Clinical Outcomes in Chronic Spontaneous Urticaria in Patients Receiving Omalizumab for Several Years
  73. Allergy rhinitis: similarities and differences between children and adults
  74. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion
  75. Estudio de carcinoma medular de tiroides a partir de un caso índice
  76. Induction of tolerance to different types of fish through desensitization with hake
  77. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis
  78. Management of chronic spontaneous urticaria in routine clinical practice: A Delphi-method questionnaire among specialists to test agreement with current European guidelines statements
  79. Allergic rhinitis causes loss of smell in children: The OLFAPEDRIAL study
  80. Pros and Cons of Clinical Basophil Testing (BAT)
  81. Basophil activation testing in diagnosis and monitoring of allergic disease – an overview
  82. Valoración de tutores clínicos y estudiantes de medicina respecto a las rotaciones en centros de atención primaria y hospitales
  83. Technical flaws in multiple-choice questions in the access exam to medical specialties (“examen MIR”) in Spain (2009–2013)
  84. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria
  85. Eosinophilic Bronchitis Caused By Exposure to Wheat Flour in the Workplace
  86. Comparable actions of omalizumab on mast cells and basophils
  87. The Incidence of Perioperative Sensitivity Reactions
  88. Lower limb function and 10-year survival in population aged 75 years and older
  89. Validation of The Spanish Version of The Urticaria Activity Score (Uas) and Its Use Over One Week (Uas7)
  90. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease
  91. Immunological events in chronic spontaneous urticaria
  92. Profile of omalizumab in the treatment of chronic spontaneous urticaria
  93. The Incidence of Perioperative Hypersensitivity Reactions
  94. Are all new allergens in TRUE Test®essential for a baseline set?
  95. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema
  96. Management of urticaria: not too complicated, not too simple
  97. Identification and Characterization of a New Oil Body Fraction Peanut Allergen
  98. Satisfacción de los estudiantes ante una sesión de exploración cardiológica impartida por compañeros entrenados
  99. A Follow-up Study to Monitor Adult Height Among Spanish Children with Growth Hormone Deficiency Who Received Biosimilar Human Recombinant Growth Hormone (Omnitrope®) During a Phase III Clinical Trial
  100. Management of angioedema without urticaria in the emergency department
  101. Nanoparticle based-immunotherapy against allergy
  102. Immunogenicity of Peanut Proteins Containing Poly(Anhydride) Nanoparticles
  103. Perioperative Reactions: Are They So Infrequent?
  104. The usefulness of plasma histamine and different tryptase cut-off points in the diagnosis of peranaesthetic hypersensitivity reactions
  105. Pomegranate (Punica granatum L.) Expresses Several nsLTP Isoforms Characterized by Different Immunoglobulin E-Binding Properties
  106. Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain
  107. A Randomized Trial of Cardiopulmonary Resuscitation Training for Medical Students
  108. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice
  109. Bilastine for the treatment of urticaria
  110. Recently introduced foods as new allergenic sources: Sensitisation to Goji berries (Lycium barbarum)
  111. Analysis of the Association Between Food Allergy and Sensitization to Ltp and Profilin
  112. The Absence of Oil Body Proteins in Allergenic Extract Might Be Involved in False-Negative Diagnosis of Some Peanut Allergic Patients
  113. Pru p 3 acts as a strong sensitizer for peanut allergy in Spain
  114. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria
  115. Development of poly(anhydride) nanoparticles loaded with peanut proteins: The influence of preparation method on the immunogenic properties
  116. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study
  117. Nuevas formas farmacéuticas para el tratamiento de enfermedades alérgicas
  118. Research needs in allergy: an EAACI position paper, in collaboration with EFA
  119. Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy
  120. Assessing Degree of Flowering Implicates Multiple <i>Chenopodiaceae/Amaranthaceae</i> Species in Allergy
  121. Can component-based microarray replace fluorescent enzimoimmunoassay in the diagnosis of grass and cypress pollen allergy?
  122. Pharmacokinetic evaluation of levocetirizine
  123. Omalizumab is effective in nonautoimmune urticaria
  124. Identification and quantification of tomato allergens: in vitro characterization of six different varieties
  125. Ara H 9 Is The Main Allergen In Peanut Allergic Patients In The Mediterranean Area Regardless The Symptom Severity
  126. Diagnostic Reliability Of The Component-based Allergen-microarray In Grass, Cypress And Olive Pollens Allergy
  127. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: The PEDRIAL study
  128. Distinguishing Male Juvenile Offenders through Personality Traits, Coping Strategies, Feelings of Guilt and Level of Anger
  129. Creating Biomimetic Polymeric Surfaces by Photochemical Attachment and Patterning of Dextran
  130. Serum total tryptase levels are increased in patients with active chronic urticaria
  131. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - The ADRIAL cohort study
  132. Differences In The Immunologic Response To Peanut Allergen Depending Upon The Route, Lipid Content And Peanut Roasting In An Animal Model
  133. In vitro Diagnosis of Anaphylaxis
  134. Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine
  135. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne
  136. Dermatophagoides farinae-specific immunotherapy in atopic dogs with hypersensitivity to multiple allergens: A randomised, double blind, placebo-controlled study
  137. Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer
  138. Chronic urticaria: do urticaria nonexperts implement treatment guidelines? A survey of adherence to published guidelines by nonexperts
  139. Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer
  140. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis
  141. Exercise-induced hypersensitivity syndromes in recreational and competitive athletes: a PRACTALL consensus report (what the general practitioner should know about sports and allergy)
  142. Molecular Diagnosis by Microarray Technology in Polysensitized Atopic Patients
  143. Gantrez® AN nanoparticles as an adjuvant for oral immunotherapy with allergens
  144. Chronic urticaria: What is new, where are we headed
  145. Intradermal immunization with ovalbumin-loaded poly-?-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice
  146. Progress and Challenges in the Understanding of Chronic Urticaria
  147. Progress and Challenges in the Understanding of Chronic Urticaria
  148. Usefulness Of Specific Ige Determination To Recombinant Grass Pollen Allergens (cap-feia) In Pollinic Patients
  149. Development of a Novel Vaccine Delivery System Based on Gantrez Nanoparticles
  150. Study of the Role of Basophils in Skin Biopsies of Urticaria
  151. Allergic Contact Dermatitis to Diallyl Disulphide in Spain
  152. Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli
  153. Gantrez® AN nanoparticles do not alter allergenicity of Lollium extract
  154. Comments regarding 'Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells' by Asero et al. M. Ferrer
  155. Urticaria crónica: estudio etiológico prospectivo e importancia del síndrome autoinmune
  156. IL3 effect on basophils histamine release upon stimulation with chronic urticaria sera
  157. Pru p 3 (LTP) content in peach extracts
  158. Siberian hamster: a new indoor source of allergic sensitization and respiratory disease
  159. Secretion of Cytokines, Histamine and Leukotrienes in Chronic Urticaria
  160. Intracellular cytokine IL4 and INF-gamma production in lymphocytes from patients with chronic urticaria
  161. Amiodarone-induced angioedema
  162. Complement dependence of histamine release in chronic urticaria☆☆☆
  163. Importance of food allergy in atopic dermatitis
  164. In vitro antigen‐specific sulphidoleukotriene production in patients allergic to Dermatophagoides pteronyssinus
  165. Comparative studies of functional and binding assays for IgG anti-FcϵRIα (α-subunit) in chronic urticaria☆☆☆★★★
  166. Sulphidoleukotriene and Histamine Releasability in Atopic Patients
  167. 406 Sulphidoleukotriene releasability in pollinic patients
  168. Specific Immunotherapy Induces Changes in Spontaneous IgE Synthesis
  169. Hill activity and anthocyanin levels in Mangifera indica